Your browser doesn't support javascript.
Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients
Journal of Gastroenterology & Hepatology ; 36(1):204-207, 2021.
Article in English | MEDLINE | ID: covidwho-1032413
ABSTRACT
BACKGROUND AND

AIM:

Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether nondiabetic patients with metabolic dysfunction are also more prone to more severe disease. The association of metabolic associated fatty liver disease (MAFLD) with COVID-19 severity in nondiabetic patients was investigated here.

METHODS:

The study cohort comprised 65 patients with (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (11) and age (+/-5 years). The association between the presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis.

RESULTS:

In nondiabetic patients with COVID-19, the presence of MAFLD was associated with a four-fold increased risk of severe COVID-19;the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex, and coexisting morbid conditions.

CONCLUSION:

Health-care professionals caring for nondiabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with MAFLD.

Full text: Available Collection: Databases of international organizations Database: MEDLINE Type of study: Prognostic study Language: English Journal: Journal of Gastroenterology & Hepatology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: MEDLINE Type of study: Prognostic study Language: English Journal: Journal of Gastroenterology & Hepatology Year: 2021 Document Type: Article